Design, Synthesis, and Evaluation of Braylin Derivatives as Novel PDE4 Inhibitors with Anti-Inflammatory Effects
Open Access
- 23 April 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 516
Abstract
Background/Objectives: PDE4 is a key regulator of cAMP signaling and a clinically validated anti-inflammatory target; however, the use of PDE4 inhibitors is often limited by adverse effects such as nausea, vomiting, and diarrhea. The natural compound braylin was previously identified as a novel PDE4 inhibitor scaffold, exhibiting an IC50 of 0.96 µM. Using the PDE4–braylin co-crystal structure, we conducted structure-based design and optimization to enhance its potency. Methods: A series of novel braylin derivatives was synthesized and characterized. Their inhibitory activities against PDE4D were evaluated via enzymatic assays, and binding thermodynamics were analyzed by isothermal titration calorimetry (ITC). Molecular modeling was used to predict binding modes, and anti-inflammatory effects were assessed in LPS-stimulated macrophages. Results: Structure-guided optimization yielded lead compound L27, which showed significantly improved PDE4D inhibition (IC50 = 67 nM) and high-affinity binding (Kd = 45 nM) as confirmed by ITC. L27 also exhibited remarkable selectivity against PDE isoforms. Molecular simulations highlighted key interactions with Gln369 and hydrophobic residues in the PDE4 active site. In cellular assays, L27 dose-dependently suppressed LPS-induced inflammation in macrophages at non-cytotoxic concentrations with efficacy comparable to roflumilast. Conclusions: We developed L27, a potent and selective PDE4 inhibitor derived from natural braylin. It demonstrated promising in vitro anti-inflammatory activity and represents a valuable lead for further therapeutic development.Keywords
Funding Information
- National Natural Science Foundation of China (22377023)
- National Natural Science Foundation of China (22277019)
- National Natural Science Foundation of China (82373732)
- National Natural Science Foundation of China (82560699)
- National Natural Science Foundation of China (82304384)
- National Natural Science Foundation of China (22467010)
- Talent Team Project in Hainan Province (HNYT20250004)
- Hainan Provincial Natural Science Foundation of China (KJRC2023B10)
- Hainan Provincial Natural Science Foundation of China (222RC556)
- Hainan Provincial Natural Science Foundation of China (823CXTD375)
- Hainan Provincial Natural Science Foundation of China (324MS018)
- Hainan Provincial Natural Science Foundation of China (824YXQN420)
- Hainan Provincial Natural Science Foundation of China (825MS072)
- Fundamental Research Funds for Hainan University (KYQD(ZR)-21031)
- Fundamental Research Funds for Hainan University (KYQD(ZR)-21108)
- Fundamental Research Funds for Hainan University (XTCX2022JKA01)
- Fundamental Research Funds for Hainan University (KYQD(ZR)-21126)
- Fundamental Research Funds for Hainan University (KYQD(ZR)-23003)
- Fundamental Research Funds for Hainan University (KYQD(ZR)-22010)
This publication has 30 references indexed in Scilit:
- Discovery of pinoresinol dimethyl ether as a natural PDE4 inhibitor with anti-psoriatic effectsBioorganic Chemistry, 2025
- Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effectsChinese Chemical Letters, 2024
- Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effectsChinese Chemical Letters, 2024
- Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axisActa Pharmaceutica Sinica B, 2022
- Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effectsBiochemical Pharmacology, 2022
- Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementiaActa Pharmaceutica Sinica B, 2022
- Free energy perturbation (FEP)-guided scaffold hoppingActa Pharmaceutica Sinica B, 2021
- Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-AnalysisDermatology and Therapy, 2020
- Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic ArthritisAmerican Journal of Clinical Dermatology, 2017
- The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinataBiochemical Pharmacology, 2017